Intra-Cellular Therapies Inc
(MEX:ITCI)
MXN
1529.77
0 (0%)
Market Cap: 191.75 Bil
Enterprise Value: 172.16 Bil
PE Ratio: 0
PB Ratio: 8.38
GF Score: 38/100 
Intra-Cellular Therapies Inc at UBS BioPharma Conference Transcript
Nov 08, 2023 / 04:00PM GMT
Release Date Price:
MXN1135.67
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst
Thanks, everybody. Welcome to UBS Biopharma Conference in Miami. My name is Ash Verma. I'm a SMID-cap biotech and spec pharma analyst at UBS, and our next company is Intra-Cellular Therapies. And with me today, I have Sharon Mates and Mark Neumann from Intra-Cellular. How are you doing?
Mark Neumann
Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer
Very good.
Ashwani Verma;Sharon Mates
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst;Intra-Cellular
Yes. Thanks for joining us. I mean so yes, like Intra-Cellular Therapies or ITCI, it's something that I've been following for a while seen us focus biotherapy. Sharon, it might be helpful if you can just give like a quick background for investors that might not be familiar with the story, and then we can dive into the questions.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers